Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-093260
Filing Date
2025-07-02
Accepted
2025-07-02 17:29:28
Documents
96
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 20-F vrax-20250331.htm   iXBRL 20-F 3818775
2 EX-8.1 vrax-ex8_1.htm EX-8.1 14517
3 EX-12.1 vrax-ex12_1.htm EX-12.1 10011
4 EX-12.2 vrax-ex12_2.htm EX-12.2 9155
5 EX-13.1 vrax-ex13_1.htm EX-13.1 7945
6 EX-13.2 vrax-ex13_2.htm EX-13.2 7959
7 GRAPHIC img135695548_0.jpg GRAPHIC 63027
8 GRAPHIC img135695548_1.jpg GRAPHIC 5643
  Complete submission text file 0000950170-25-093260.txt   14605086

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vrax-20250331.xsd EX-101.SCH 1832618
98 EXTRACTED XBRL INSTANCE DOCUMENT vrax-20250331_htm.xml XML 3174122
Mailing Address BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE X0 ML1 5UH
Business Address BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE X0 ML1 5UH 44 020 7788 7414
Virax Biolabs Group Ltd (Filer) CIK: 0001885827 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: 20-F | Act: 34 | File No.: 001-41440 | Film No.: 251102723
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)